This legislation directs the Secretary of Commerce to promote competitiveness in United States biomanufacturing. Within one year of enactment, the Secretary must designate a senior official to lead these efforts, focusing on commercial competitiveness for biomanufacturing and biomanufactured products. This official will oversee various activities designed to strengthen the domestic industry. Key activities include identifying federal processes, resources, and barriers to private sector investment, market adoption, and domestic production, especially those arising from unclear or duplicative federal processes. The official will also pinpoint supply chain vulnerabilities, chokepoints, and reliance on foreign adversaries for critical biomanufacturing inputs . Opportunities for strengthening domestic production, supplier diversification, and supply chain resilience will also be identified. The bill requires biennial assessments of the current and foreseeable availability of critical biomanufacturing inputs and domestic production capacity. These assessments will evaluate the extent of reliance on foreign adversaries, identify vulnerabilities, and assess the impact of unaddressed issues on U.S. commerce and biomanufacturing. Based on these findings, the Secretary must prepare prioritized action plans to mitigate identified risks and barriers. To improve transparency and industry guidance, the Secretary must identify and make publicly available industry-led, evidence-based practices related to the commercialization of biomanufacturing processes and products. These practices cover areas such as production readiness, operational consistency, supplier qualification, and the protection of trade secrets. Consultations with non-Federal entities, prioritizing U.S. and trusted stakeholders, are mandated for this process. Furthermore, the bill requires a report mapping all relevant federal processes that may apply to the commercialization of biomanufactured products and critical inputs, highlighting overlaps, gaps, and opportunities for improvement. The Secretary of Health and Human Services (acting through the FDA Commissioner) and the Administrator of the Environmental Protection Agency must designate points of contact to assist non-Federal entities with information on their respective processes. A publicly available web resource will consolidate relevant federal information and practices. The legislation ensures the protection of voluntarily submitted nonpublic information, such as trade secrets or sensitive supply-chain vulnerability data, from public disclosure. Regular reports summarizing actions, assessments, and action plans will be submitted to appropriate congressional committees and made publicly available. Most requirements of the bill are set to terminate five years after its enactment.